Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

Summary

This prospective multicenter clinical study was designed to assess the efficacy and safety of decitabine in combination with low-dose cytarabine induction treatment for elderly patients with newly diagnosed acute myeloid leukemia (AML).

Conditions

• Acute Myeloid Leukemia, Adult

Interventions

DRUG

Decitabine

All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).

DRUG

Cytarabine

Sponsors & Collaborators

• Binzhou Medical University

  collaborator OTHER

• Shengli Oilfield Hospital

  collaborator OTHER

• Heze Municipal Hospital

  collaborator OTHER

• Jinan Military Genaral Hospital

  collaborator UNKNOWN

• Jinan Central Hospital

  collaborator OTHER

• Jining Medical University

  collaborator OTHER

• Linyi People's Hospital

  collaborator OTHER

• Qingdao University

  collaborator OTHER

• Rizhao People's Hospital

  collaborator OTHER

• Qianfoshan Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University (Qingdao)

  collaborator OTHER

• Taian City Central Hospital

  collaborator OTHER

• Taishan Medical University Affiliated Hospital

  collaborator OTHER

• Weihai Municipal Hospital

  collaborator OTHER

• Weifang Medical University

  collaborator OTHER

• Zibo First Hospital

  collaborator OTHER

• Central Hospital of Zibo

  collaborator OTHER

• Chunyan Ji

  lead OTHER

Principal Investigators

• Chunyan Ji, Doctor · Shandong University

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

60 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-12-31

Primary Completion

2018-12-31

Completion

2019-12-31